CLAIMS

1. Use of an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment in the manufacture of a medicament for therapy or prevention of symptoms of illness in a subject in need thereof, wherein such subject is human, and wherein said antibody or fragment binds to the N-terminal part of ADM (amino acids 1-21; SEQ ID NO:4),
   wherein the symptoms of illness are selected from nausea, headache, muscle aches, back pain, shivering, and/or vomiting, wherein the illness is characterized by an amount of C-reactive protein (CRP) in a sample which is ≥ 10 mg/L, and/or wherein the amount of TNF in a sample is ≥ 50 pg/ml, and/or wherein the amount of bio-ADM in a sample is ≥ 43pg/ml, and wherein said sample is selected from the group consisting of whole blood, plasma and serum.

2. The use according to claim 1, wherein the illness is selected from an inflammatory condition, autoimmune disease, metabolic disease, brain disease, cardiovascular disease and drug-induced disease.

3. The use according to any one of claims 1 to 2, wherein said antibody or antibody fragment is monospecific.

4. The use according to any one of claims 1 to 3, wherein said antibody or fragment exhibits a binding affinity to ADM of at least 10^{-7} M by label-free surface plasmon resonance using a Biacore 2000 system.

5. The use according to any one of claims 1 to 4, wherein said antibody or fragment recognizes and binds to the N-terminal end (amino acid 1) of ADM.

6. The use according to any one of claims 1 to 5, wherein said antibody or fragment is an ADM stabilizing antibody or fragment or scaffold that enhances the half-life (t1/2 half retention time) of ADM in serum, blood, plasma at least 10 %, preferably at least, 50 %, more preferably > 50 %, most preferably > 100 %.

7. The use according to any one of claims 1 to 6, wherein said antibody or fragment blocks the bioactivity of ADM not more than 80 %, preferably not more than 50% using hADM 22-52 as a reference antagonist in CHO-K1 cells expressing human recombinant ADM receptor.

8. The use according to any one of claims 1 to 7, wherein said subject undergoes chemotherapy, treatment with biological biologics, antibiotics, or treatment with anti-viral compounds.

9. The use according to any one of claims 1 to 8, wherein said antibody or fragment is a human monoclonal antibody or fragment that binds to ADM or an antibody fragment thereof wherein the heavy chain comprises the sequences:

CDR1: SEQ ID NO: 5
GYTFSRYW

CDR2: SEQ ID NO: 6
ILPGSGST

CDR3: SEQ ID NO: 7
TEGYEYDGFDY

and wherein the light chain comprises the sequences:

CDR1: SEQ ID NO: 8
QSIVYSNGNTY

CDR2:
RVS

CDR3: SEQ ID NO: 9
FQGSHIPYT.

10. Pharmaceutical formulation for use in therapy or prevention of symptoms of illness or for the use in therapy or prevention of an illness characterized by such symptoms in a subject in need thereof comprising an antibody or fragment as defined in any one of claims 1 to 9.

11. Use of a pharmaceutical formulation comprising an antibody or fragment as defined in any one of claims 1 to 10.